XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
IAC
Angi Inc.
Redeemable Noncontrolling Interests
Total IAC Shareholders' Equity
Total IAC Shareholders' Equity
IAC
Total IAC Shareholders' Equity
Angi Inc.
Common Stock
Common Stock, $0.0001 par value
Common Stock
Class B common stock, $0.0001 par value
Additional Paid-in-Capital
Additional Paid-in-Capital
Angi Inc.
(Accumulated Deficit) Retained Earnings
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive (Loss) Income
Angi Inc.
Treasury Stock
Treasury Stock
IAC
Noncontrolling Interests
Noncontrolling Interests
Angi Inc.
Balance at beginning of period at Dec. 31, 2023       $ 33,378                            
Increase (Decrease) in Redeemable Noncontrolling Interests                                    
Net earnings (loss)       741                            
Adjustment of noncontrolling interests to redemption amount       (3,869)                            
Other       (1,571)                            
Balance at end of period at Sep. 30, 2024       28,679                            
Balance at beginning of period at Dec. 31, 2023 $ 6,755,003       $ 6,077,861     $ 8 $ 1 $ 6,340,312   $ 923 $ (10,942)   $ (252,441)   $ 677,142  
Balance at beginning of period (in shares) at Dec. 31, 2023               84,465 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Net earnings (loss) (334,681)       (340,920)             (340,920)         6,239  
Other comprehensive (loss) income, net of income taxes 1,760       1,323               1,323       437  
Stock-based compensation expense 90,592       58,144         58,144             32,448  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)               358                    
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (14,637)   $ (5,652)   (14,637)   $ 5,879     (14,637) $ 5,868     $ 11       $ (11,531)
Purchase of treasury stock     (25,772)       (25,772)       (25,772)              
Purchase of noncontrolling interests (16,019)       (11,296)         (11,296)             (4,723)  
Adjustment of noncontrolling interests to redemption amount 3,869       3,869         3,869                
Adjustment to the liquidation value of Vivian Health preferred shares 0       5,497         5,497             (5,497)  
Other 96       96         96                
Balance at end of period (in shares) at Sep. 30, 2024               84,823 5,789                  
Balance at end of period at Sep. 30, 2024 6,454,559       5,760,044     $ 8 $ 1 6,362,081   (339,997) (9,608)   (252,441)   694,515  
Balance at beginning of period at Jun. 30, 2024       29,132                            
Increase (Decrease) in Redeemable Noncontrolling Interests                                    
Net earnings (loss)       832                            
Adjustment of noncontrolling interests to redemption amount       (27)                            
Other       (1,258)                            
Balance at end of period at Sep. 30, 2024       28,679                            
Balance at beginning of period at Jun. 30, 2024 6,696,078       6,008,365     $ 8 $ 1 6,363,548   (96,278) (6,473)   (252,441)   687,713  
Balance at beginning of period (in shares) at Jun. 30, 2024               84,683 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Net earnings (loss) (238,277)       (243,719)             (243,719)         5,442  
Other comprehensive (loss) income, net of income taxes (2,510)       (3,142)               (3,142)       632  
Stock-based compensation expense 29,545       18,209         18,209             11,336  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)               140                    
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (5,822)   (909)   (5,822)   3,620     (5,822) 3,613     7       (4,529)
Purchase of treasury stock     (7,588)       (7,588)       (7,588)              
Purchase of noncontrolling interests (16,019)       (11,296)         (11,296)             (4,723)  
Adjustment of noncontrolling interests to redemption amount 27       27         27                
Adjustment to the liquidation value of Vivian Health preferred shares 0       1,356         1,356             (1,356)  
Other 34       34         34                
Balance at end of period (in shares) at Sep. 30, 2024               84,823 5,789                  
Balance at end of period at Sep. 30, 2024 6,454,559       5,760,044     $ 8 $ 1 6,362,081   (339,997) (9,608)   (252,441)   694,515  
Balance at beginning of period at Dec. 31, 2024 25,415     25,415                            
Increase (Decrease) in Redeemable Noncontrolling Interests                                    
Net earnings (loss)       244                            
Adjustment of noncontrolling interests to redemption amount       (347)                            
Other       (33)                            
Balance at end of period at Sep. 30, 2025 25,279     25,279                            
Balance at beginning of period at Dec. 31, 2024 6,278,973       5,577,898     $ 8 $ 1 6,380,700   (538,974) (11,396)   (252,441)   701,075  
Balance at beginning of period (in shares) at Dec. 31, 2024               84,831 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Net earnings (loss) (25,916)       (27,232)             (27,232)         1,316  
Other comprehensive (loss) income, net of income taxes 328       (105)               (105)       433  
Stock-based compensation expense 15,415       13,270         13,270             2,145  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)               1,408                    
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (57,913)   (4,572)   (57,913)   (8,260)     (57,913) (8,264)     $ 4       $ 3,688
Forfeiture of IAC's former CEO's restricted common stock award (in shares)               (3,000)                    
Withholding taxes paid on IAC's transfer of Angi Inc. Class B shares to its former CEO (9,347)       (9,347)         (9,347)                
Purchase of treasury stock   $ (302,407) $ (10,688)     $ (302,407) $ (10,688)       $ (10,688)         $ (302,407)    
Adjustment of noncontrolling interests to redemption amount 347       347         347                
Adjustment to the liquidation value of Vivian Health preferred shares 0       (2,198)         (2,198)             2,198  
Distribution of IAC's investment in Angi Inc. (1,065,994)       (1,065,994)         (1,065,612)     (382)          
Elimination of Angi Inc. noncontrolling interest 0       682,927         682,927             (682,927)  
Other 188       188         188                
Balance at end of period (in shares) at Sep. 30, 2025               83,239 5,789                  
Balance at end of period at Sep. 30, 2025 4,818,414       4,790,486     $ 8 $ 1 5,923,410   (566,206) (11,879)   (554,848)   27,928  
Balance at beginning of period at Jun. 30, 2025       25,279                            
Increase (Decrease) in Redeemable Noncontrolling Interests                                    
Net earnings (loss)       156                            
Adjustment of noncontrolling interests to redemption amount       (156)                            
Balance at end of period at Sep. 30, 2025 25,279     $ 25,279                            
Balance at beginning of period at Jun. 30, 2025 4,937,503       4,911,092     $ 8 $ 1 5,920,478   (544,327) (11,102)   (453,966)   26,411  
Balance at beginning of period (in shares) at Jun. 30, 2025               82,946 5,789                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Net earnings (loss) (21,893)       (21,879)             (21,879)         (14)  
Other comprehensive (loss) income, net of income taxes (777)       (777)               (777)          
Stock-based compensation expense 16,992       16,639         16,639             353  
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (in shares)               293                    
Issuance of common stock pursuant to stock-based awards, net of withholding taxes (12,734)       (12,734)         (12,734)                
Purchase of treasury stock   $ (100,882)       $ (100,882)                   $ (100,882)    
Adjustment of noncontrolling interests to redemption amount 156       156         156                
Adjustment to the liquidation value of Vivian Health preferred shares 0       (1,178)         (1,178)             1,178  
Other 49       49         49                
Balance at end of period (in shares) at Sep. 30, 2025               83,239 5,789                  
Balance at end of period at Sep. 30, 2025 $ 4,818,414       $ 4,790,486     $ 8 $ 1 $ 5,923,410   $ (566,206) $ (11,879)   $ (554,848)   $ 27,928